5 completed. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Pharmacokinetics Study in Healthy Japanese Volunteers ABX464, Placebo - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 48 | 2021-09-27 | 2023-01-26 |
| Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 Caffeine, ABX464, Fluvoxamine - Healthy | Phase 1 | Completed | Abivax S.A. | 59 | 2020-12-17 | 2026-11-09 |
| A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults ABX464 150mg, ABX464 50mg - HIV Infections, Health Volunteers | Phase 1 / Phase 2 | Completed | Abivax S.A. | 36 | 2017-03-27 | 2023-03-31 |
| Food Effect on Pharmacokinetic Parameters of ABX464 ABX464 Single dose, ABX464 Repeated dose - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 48 | 2014-09-01 | 2016-04-08 |
| ABX464 First in Man Study ABX464 - Healthy Volunteers | Phase 1 | Completed | Abivax S.A. | 24 | 2014-03-01 | 2024-05-17 |
HIV Infections (1)
Abivax S.A. (5)
France (1) · Japan (1) · Mauritius (1) · Spain (1) · United Kingdom (1)
Paul Gineste (1)